Research programme: pain therapeutics - Reviva Pharmaceuticals
Alternative Names: RP8000 - Reviva PharmaceuticalsLatest Information Update: 16 Jul 2016
At a glance
- Originator Reviva Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Pain in USA (PO)
- 27 Jun 2012 Research programme: pain therapeutics - Reviva Pharmaceuticals is available for licensing as of 27 Jun 2012. www.revivapharma.com
- 18 May 2012 Early research in Pain in USA (PO)